Children with inherited bone marrow failure are at an increased risk for developing head & neck cancer, skin cancer & blood cancers.Currently, the NIH has a study looking at cancer susceptibility to identify new genes that may contribute to cancer.
Cell lines + patient-derived xenografts (PDXs) enable biological and preclinical therapeutic studies informing clinical trials. Developing, characterizing and insuring distribution of such models for childhood cancers should be funded by NCI.
Grants on childhood cancer can be assigned to a study section with no pediatric oncologists and often a single reviewer is a pediatric oncologist. Funding is by percentile; a fair and informed review requires a pediatric oncology study section.
Young Cancer patients are treated with highly caustic chemotherapies in order to halt the growth of solid tumors.
Young survivors are at great risk of secondary cancers as a result of those treatments. Better methods are needed.
Young Cancer Survivors often experience high levels of stress and anxiety following treatment. Those treated as adolescents and early young adulthood often face isolation and lack of life managment skills. Awareness and support are needed.
A subset of pediatric melanoma arises from congenital tumors present at birth. Large or giant congenital melanocytic nevi (CMN) represent one of such cases. Due to rarity of the disease, funding is scarce and no targeted chemotherapy is available.
The practice of Precision Medicine involves genome sequencing (study of genetic and molecular features of an individual pediatric cancer patient) to identify mutations in their DNA.
The goal, with a focus on exosomes, is ultimately to be able to predict and pre-empt the process -- early, if possible, but even in advanced metastasis in order for people to be able to live long lives with cancer.
Natural Killer (NK) cell research, already in a Phase I clinical trial, could hold hope for children with certain brain cancers.
National Cooperative Drug Discovery/Development Groups (NCDDG) should be used as a funding mechanism to create multidisciplinary research groups and partnerships for the discovery and development of pharmacological agents to treat pediatric cancer.
Develop a minimal invasive blood test to increase frequency and long term monitoring of relapse in ALL patients to enable optimal treatment outcome. The blood test is based on 3 microRNA that predict relapse in bone marrow samples taken at diagnosis.
Many forms of cancer in children are resistant to conventional therapies. We need new, safe ways to overcome this resistance and allow chemotherapy to work. Cannabis extracts are very likely to hold this answer.
Cardiovascular diseases and cancer are co-top killers of patients among all diseases. The adverse effects of anticancer treatments on cardiac function could take the patients' lives as a secondary killer after a 'successful' anticancer treatment.
Plethora of clinical research data about late effects of treatment for childhood cancers is available for prevalence, mortality, monitoring of factors with regards to tumor growth, relapse, treatment modalities and genetic predispositions.
MY IDEA IS TO DESIGN A DRUG DELIVERY DEVICE USING IONTOPHORESIS AS TRANS DERMAL DELIVERY USING ULTRASONIC WAVES FOR SYNERGISTIC EFFECT ON APOPTOSIS IN TUMOR CELLS AND REAL TIME TUMOR SIZE MONITORING OF DRUG EFFECT ON SOLID TUMORS.